Replies to post #256085 on Biotech Values

[DewDiligence]

ENTA—Pretty good summary by Reuters—(the stock is now +70% rather than +40% when this newswire was issued around 1pm ET):

https://www.reuters.com/business/healthcare-pharmaceuticals/enantas-rsv-treatment-misses-main-goal-mid-stage-study-2025-09-29/